<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34975586</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-0640</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in psychiatry</Title>
          <ISOAbbreviation>Front Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>789982</StartPage>
          <MedlinePgn>789982</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">789982</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2021.789982</ELocationID>
        <Abstract>
          <AbstractText>Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Over the past twenty years, research on the disease and its characteristics and treatment options has grown exponentially. The first-line pharmacologic treatment of ADHD is stimulants, which have a response rate of ~70%. With the support of four phase 3 studies involving more than 1,000 pediatric patients 6-17 years old, the FDA has approved the non-stimulant, serotonin-norepinephrine modulating agent (SNMA) viloxazine in an extended-release capsule (viloxazine ER) for treatment of ADHD in children aged 6-17. Viloxazine modulates serotonergic activity as a selective 5-HT2<sub>2B</sub> receptor antagonist and 5-HT<sub>2C</sub> receptor agonist and moderately inhibits norepinephrine transporter (NET), thus blocking the reuptake of norepinephrine. A phase 2 study by Johnson et al. found that once-daily dosing of viloxazine ER in 200, 300, or 400 mg dosages in children with ADHD for eight weeks resulted in a statistically significant reduction of ADHD-RS-IV total score. A <i>post hoc</i> analysis of data from four phase 3, randomized, placebo-controlled, double-blind, three-arm, clinical trials by Faraone et al. found that early response to viloxazine treatment, defined as a change in ADHD-RS-5 total score at week 2, best predicted the treatment response at week 6 [75% positive predictive power (PPP), 75% sensitivity]. Proper treatment of the symptoms and comorbidities associated with ADHD is crucial in improving a patient's quality of life, cognitive function, and overall therapeutic outcomes. Viloxazine's mechanism of action, clinical effects, and limited side effect profile point toward the drug's relevance in the treatment of ADHD.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Edinoff, Akuly, Wagner, Boudreaux, Kaplan, Yusuf, Neuchat, Cornett, Boyer, Kaye and Kaye.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Edinoff</LastName>
            <ForeName>Amber N</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akuly</LastName>
            <ForeName>Haseeb A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wagner</LastName>
            <ForeName>John H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boudreaux</LastName>
            <ForeName>Megan A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaplan</LastName>
            <ForeName>Leah A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yusuf</LastName>
            <ForeName>Shadman</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neuchat</LastName>
            <ForeName>Elisa E</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Florida International University, Miami, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cornett</LastName>
            <ForeName>Elyse M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boyer</LastName>
            <ForeName>Andrea G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>Family Psychiatry and Psychology Associates, Cary, NC, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaye</LastName>
            <ForeName>Adam M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Thomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaye</LastName>
            <ForeName>Alan D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Psychiatry</MedlineTA>
        <NlmUniqueID>101545006</NlmUniqueID>
        <ISSNLinking>1664-0640</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADHD</Keyword>
        <Keyword MajorTopicYN="N">neuropsychiatric disorder</Keyword>
        <Keyword MajorTopicYN="N">non-stimulant</Keyword>
        <Keyword MajorTopicYN="N">pediatrics</Keyword>
        <Keyword MajorTopicYN="N">serotonin-norepinephrine modulating agent</Keyword>
        <Keyword MajorTopicYN="N">viloxazine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34975586</ArticleId>
        <ArticleId IdType="pmc">PMC8718796</ArticleId>
        <ArticleId IdType="doi">10.3389/fpsyt.2021.789982</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Austerman J. ADHD and behavioral disorders: assessment, management, and an update from DSM-5. Cleve Clin J Med. (2015) 82(11 Suppl 1):S2–7. 10.3949/ccjm.82.s1.01</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.82.s1.01</ArticleId>
            <ArticleId IdType="pubmed">26555810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banaschewski T, Becker K, Döpfner M, Holtmann M, Rösler M, Romanos M. Attention-Deficit/Hyperactivity disorder. Dtsch Ärztebl Int. (2017) 114:149–59. 10.3238/arztebl.2017.0149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3238/arztebl.2017.0149</ArticleId>
            <ArticleId IdType="pmc">PMC5378980</ArticleId>
            <ArticleId IdType="pubmed">28351467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Health. (2018) 21:173–6. 10.1136/ebmental-2018-300050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ebmental-2018-300050</ArticleId>
            <ArticleId IdType="pubmed">30301823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PubChem. Viloxazine . Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/5666 (accessed June 8, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. (2007) 32:643–54. 10.1093/jpepsy/jsl054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jpepsy/jsl054</ArticleId>
            <ArticleId IdType="pubmed">17569716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown LK, Hadley W, Stewart A, Lescano C, Whiteley L, Donenberg G, et al. . Psychiatric disorders and sexual risk among adolescents in mental health treatment. J Consult Clin Psychol. (2010) 78:590–7. 10.1037/a0019632</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/a0019632</ArticleId>
            <ArticleId IdType="pmc">PMC2911994</ArticleId>
            <ArticleId IdType="pubmed">20658815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc JINS. (2002) 8:655–72. 10.1017/S1355617702801345</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1355617702801345</ArticleId>
            <ArticleId IdType="pubmed">12164675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. (2014) 48:209–25. 10.1177/1060028013510699</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028013510699</ArticleId>
            <ArticleId IdType="pubmed">24259638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association;  (2013). 947 p.</Citation>
        </Reference>
        <Reference>
          <Citation>Barbas H, Medalla M, Alade O, Suski J, Zikopoulos B, Lera P. Relationship of prefrontal connections to inhibitory systems in superior temporal areas in the rhesus monkey. Cereb Cortex. (2005) 15:1356–70. 10.1093/cercor/bhi018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bhi018</ArticleId>
            <ArticleId IdType="pubmed">15635060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. (2002) 52:785–94. 10.1016/S0006-3223(02)01412-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(02)01412-9</ArticleId>
            <ArticleId IdType="pubmed">12372650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SCR, Simmons A, et al. . Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. (1999) 156:891–6. 10.1176/ajp.156.6.891</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.156.6.891</ArticleId>
            <ArticleId IdType="pubmed">10360128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. (2009) 57:579–89. 10.1016/j.neuropharm.2009.07.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2009.07.026</ArticleId>
            <ArticleId IdType="pubmed">19627998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. (2019) 24:390–408. 10.1038/s41380-018-0116-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-018-0116-3</ArticleId>
            <ArticleId IdType="pubmed">29955166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Diagnosis and management of ADHD in children. Am Fam Physician. (2014) 90:456–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25369623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern Med Rev J Clin Ther. (2011) 16:323–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22214252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, et al. . The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. (2017) 12:e0180355. 10.1371/journal.pone.0180355</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0180355</ArticleId>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PubChem. Viloxazine . Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/5666 (accessed June 27, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Available, online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf (accessed June 26, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>FDA Viloxazine Drug Insert . Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf (accessed June 27, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. (2020) 12:285–300. 10.2147/JEP.S256586</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth BL. 5-Ht2a serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology. (2011) 61:348–54. 10.1016/j.neuropharm.2011.01.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2011.01.012</ArticleId>
            <ArticleId IdType="pmc">PMC3110590</ArticleId>
            <ArticleId IdType="pubmed">21288474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs@FDA: FDA-Approved Drugs . Available online at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211964 (accessed June 26, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, Odebo O, Schwabe S, Wang Z, et al. . Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. (2021) 41:149–59. 10.1007/s40261-020-00992-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40261-020-00992-6</ArticleId>
            <ArticleId IdType="pmc">PMC7886742</ArticleId>
            <ArticleId IdType="pubmed">33368026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al. . Evaluation of the effect of SPN-812 (Viloxazine Extended-Release) on QTc interval in healthy adults. J Clin Psychiatry. (2020) 81:20m13395. 10.4088/JCP.20m13395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.20m13395</ArticleId>
            <ArticleId IdType="pubmed">33049804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. . A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (Viloxazine Extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. (2020) 42:1452–66. 10.1016/j.clinthera.2020.05.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al. . A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (Extended-Release Viloxazine) in children with ADHD. J Atten Disord. (2020) 24:348–58. 10.1177/1087054719836159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, et al. . Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. (2021) 296:113664. 10.1016/j.psychres.2020.113664</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2020.113664</ArticleId>
            <ArticleId IdType="pubmed">33418457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, et al. . Translating attention-deficit/hyperactivity disorder rating scale-5 and weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (Viloxazine Extended-Release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. (2021) 31:214–26. 10.1089/cap.2020.0148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2020.0148</ArticleId>
            <ArticleId IdType="pmc">PMC8066343</ArticleId>
            <ArticleId IdType="pubmed">33600233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, Adewole T, Liranso T, Schwabe S, et al. . 112 A Phase 3. CNS Spectr. (2020) 25:272–3. 10.1017/S1092852920000309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852920000309</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34975586</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-0640</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in psychiatry</Title>
          <ISOAbbreviation>Front Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>789982</StartPage>
          <MedlinePgn>789982</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">789982</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2021.789982</ELocationID>
        <Abstract>
          <AbstractText>Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Over the past twenty years, research on the disease and its characteristics and treatment options has grown exponentially. The first-line pharmacologic treatment of ADHD is stimulants, which have a response rate of ~70%. With the support of four phase 3 studies involving more than 1,000 pediatric patients 6-17 years old, the FDA has approved the non-stimulant, serotonin-norepinephrine modulating agent (SNMA) viloxazine in an extended-release capsule (viloxazine ER) for treatment of ADHD in children aged 6-17. Viloxazine modulates serotonergic activity as a selective 5-HT2<sub>2B</sub> receptor antagonist and 5-HT<sub>2C</sub> receptor agonist and moderately inhibits norepinephrine transporter (NET), thus blocking the reuptake of norepinephrine. A phase 2 study by Johnson et al. found that once-daily dosing of viloxazine ER in 200, 300, or 400 mg dosages in children with ADHD for eight weeks resulted in a statistically significant reduction of ADHD-RS-IV total score. A <i>post hoc</i> analysis of data from four phase 3, randomized, placebo-controlled, double-blind, three-arm, clinical trials by Faraone et al. found that early response to viloxazine treatment, defined as a change in ADHD-RS-5 total score at week 2, best predicted the treatment response at week 6 [75% positive predictive power (PPP), 75% sensitivity]. Proper treatment of the symptoms and comorbidities associated with ADHD is crucial in improving a patient's quality of life, cognitive function, and overall therapeutic outcomes. Viloxazine's mechanism of action, clinical effects, and limited side effect profile point toward the drug's relevance in the treatment of ADHD.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Edinoff, Akuly, Wagner, Boudreaux, Kaplan, Yusuf, Neuchat, Cornett, Boyer, Kaye and Kaye.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Edinoff</LastName>
            <ForeName>Amber N</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akuly</LastName>
            <ForeName>Haseeb A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wagner</LastName>
            <ForeName>John H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boudreaux</LastName>
            <ForeName>Megan A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaplan</LastName>
            <ForeName>Leah A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yusuf</LastName>
            <ForeName>Shadman</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neuchat</LastName>
            <ForeName>Elisa E</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Florida International University, Miami, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cornett</LastName>
            <ForeName>Elyse M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boyer</LastName>
            <ForeName>Andrea G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>Family Psychiatry and Psychology Associates, Cary, NC, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaye</LastName>
            <ForeName>Adam M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Thomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaye</LastName>
            <ForeName>Alan D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Psychiatry</MedlineTA>
        <NlmUniqueID>101545006</NlmUniqueID>
        <ISSNLinking>1664-0640</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADHD</Keyword>
        <Keyword MajorTopicYN="N">neuropsychiatric disorder</Keyword>
        <Keyword MajorTopicYN="N">non-stimulant</Keyword>
        <Keyword MajorTopicYN="N">pediatrics</Keyword>
        <Keyword MajorTopicYN="N">serotonin-norepinephrine modulating agent</Keyword>
        <Keyword MajorTopicYN="N">viloxazine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34975586</ArticleId>
        <ArticleId IdType="pmc">PMC8718796</ArticleId>
        <ArticleId IdType="doi">10.3389/fpsyt.2021.789982</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Austerman J. ADHD and behavioral disorders: assessment, management, and an update from DSM-5. Cleve Clin J Med. (2015) 82(11 Suppl 1):S2–7. 10.3949/ccjm.82.s1.01</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.82.s1.01</ArticleId>
            <ArticleId IdType="pubmed">26555810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banaschewski T, Becker K, Döpfner M, Holtmann M, Rösler M, Romanos M. Attention-Deficit/Hyperactivity disorder. Dtsch Ärztebl Int. (2017) 114:149–59. 10.3238/arztebl.2017.0149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3238/arztebl.2017.0149</ArticleId>
            <ArticleId IdType="pmc">PMC5378980</ArticleId>
            <ArticleId IdType="pubmed">28351467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Health. (2018) 21:173–6. 10.1136/ebmental-2018-300050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ebmental-2018-300050</ArticleId>
            <ArticleId IdType="pubmed">30301823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PubChem. Viloxazine . Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/5666 (accessed June 8, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. (2007) 32:643–54. 10.1093/jpepsy/jsl054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jpepsy/jsl054</ArticleId>
            <ArticleId IdType="pubmed">17569716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown LK, Hadley W, Stewart A, Lescano C, Whiteley L, Donenberg G, et al. . Psychiatric disorders and sexual risk among adolescents in mental health treatment. J Consult Clin Psychol. (2010) 78:590–7. 10.1037/a0019632</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/a0019632</ArticleId>
            <ArticleId IdType="pmc">PMC2911994</ArticleId>
            <ArticleId IdType="pubmed">20658815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc JINS. (2002) 8:655–72. 10.1017/S1355617702801345</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1355617702801345</ArticleId>
            <ArticleId IdType="pubmed">12164675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. (2014) 48:209–25. 10.1177/1060028013510699</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028013510699</ArticleId>
            <ArticleId IdType="pubmed">24259638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association;  (2013). 947 p.</Citation>
        </Reference>
        <Reference>
          <Citation>Barbas H, Medalla M, Alade O, Suski J, Zikopoulos B, Lera P. Relationship of prefrontal connections to inhibitory systems in superior temporal areas in the rhesus monkey. Cereb Cortex. (2005) 15:1356–70. 10.1093/cercor/bhi018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bhi018</ArticleId>
            <ArticleId IdType="pubmed">15635060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. (2002) 52:785–94. 10.1016/S0006-3223(02)01412-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(02)01412-9</ArticleId>
            <ArticleId IdType="pubmed">12372650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SCR, Simmons A, et al. . Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. (1999) 156:891–6. 10.1176/ajp.156.6.891</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.156.6.891</ArticleId>
            <ArticleId IdType="pubmed">10360128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. (2009) 57:579–89. 10.1016/j.neuropharm.2009.07.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2009.07.026</ArticleId>
            <ArticleId IdType="pubmed">19627998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. (2019) 24:390–408. 10.1038/s41380-018-0116-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-018-0116-3</ArticleId>
            <ArticleId IdType="pubmed">29955166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Diagnosis and management of ADHD in children. Am Fam Physician. (2014) 90:456–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25369623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern Med Rev J Clin Ther. (2011) 16:323–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22214252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, et al. . The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. (2017) 12:e0180355. 10.1371/journal.pone.0180355</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0180355</ArticleId>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PubChem. Viloxazine . Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/5666 (accessed June 27, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Available, online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf (accessed June 26, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>FDA Viloxazine Drug Insert . Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf (accessed June 27, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. (2020) 12:285–300. 10.2147/JEP.S256586</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth BL. 5-Ht2a serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology. (2011) 61:348–54. 10.1016/j.neuropharm.2011.01.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2011.01.012</ArticleId>
            <ArticleId IdType="pmc">PMC3110590</ArticleId>
            <ArticleId IdType="pubmed">21288474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs@FDA: FDA-Approved Drugs . Available online at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211964 (accessed June 26, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, Odebo O, Schwabe S, Wang Z, et al. . Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. (2021) 41:149–59. 10.1007/s40261-020-00992-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40261-020-00992-6</ArticleId>
            <ArticleId IdType="pmc">PMC7886742</ArticleId>
            <ArticleId IdType="pubmed">33368026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al. . Evaluation of the effect of SPN-812 (Viloxazine Extended-Release) on QTc interval in healthy adults. J Clin Psychiatry. (2020) 81:20m13395. 10.4088/JCP.20m13395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.20m13395</ArticleId>
            <ArticleId IdType="pubmed">33049804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. . A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (Viloxazine Extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. (2020) 42:1452–66. 10.1016/j.clinthera.2020.05.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al. . A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (Extended-Release Viloxazine) in children with ADHD. J Atten Disord. (2020) 24:348–58. 10.1177/1087054719836159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, et al. . Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. (2021) 296:113664. 10.1016/j.psychres.2020.113664</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2020.113664</ArticleId>
            <ArticleId IdType="pubmed">33418457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, et al. . Translating attention-deficit/hyperactivity disorder rating scale-5 and weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (Viloxazine Extended-Release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. (2021) 31:214–26. 10.1089/cap.2020.0148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2020.0148</ArticleId>
            <ArticleId IdType="pmc">PMC8066343</ArticleId>
            <ArticleId IdType="pubmed">33600233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, Adewole T, Liranso T, Schwabe S, et al. . 112 A Phase 3. CNS Spectr. (2020) 25:272–3. 10.1017/S1092852920000309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852920000309</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
